Table 2.
Baseline patient characteristics
| Patient characteristics (N = 4417) | LAN (n = 2327) | OCT (n = 2090) | p value |
|---|---|---|---|
| Population, n (%) | 2327 (52.7) | 2090 (47.3) | |
| Male, n (%) | 1228 (52.8) | 1072 (51.3) | 0.3256a |
| Age, years, mean (SD) | 64.8 (12.2) | 64.4 (12.6) | 0.2722b |
| Type of NETs, n (%) | |||
| NETs with carcinoid syndrome | 299 (12.8) | 221 (10.6) | 0.0217a |
| Other functional NETS | 58 (2.5) | 51 (2.4) | 0.9983a |
| Non-functional NETs | 1434 (61.6) | 1437 (68.8) | < 0.0001a |
| NETs unclassifiable as functional or not | 536 (23.0) | 381 (18.2) | < 0.0001a |
| NET localization, n (%) | |||
| GEP-NET | 1478 (63.5) | 1278 (61.2) | 0.1118a |
| Lung | 107 (4.6) | 115 (5.5) | 0.1921a |
| Ovary/uterus | 59 (2.5) | 116 (5.6) | < 0.0001a |
| Other | 99 (4.3) | 105 (5.0) | 0.2523a |
| Multiple | 3 (0.1) | 2 (0.1) | 0.9999a |
| Unknown | 581 (25.0) | 474 (22.7) | 0.0809a |
| Follow-up time, years, median (Q1–Q3) | |||
| Overall population | 2.8 (1.6−4.3) | 3.0 (1.6−4.8) | – |
| GEP-NETs subgroup | 2.8 (1.7−4.4) | 3.2 (1.7−5.0) | – |
The localization of tumors causing a carcinoid syndrome (E340) or a metastatic disease (C77-C79) was established, if applicable, from the ICD-10 associated diagnostic code of carcinoid syndrome or metastatic tumor during the same hospital stay. The tumors searched were malignant primary neoplasms (C00-C75) and for carcinoid syndromes, in situ and benign neoplasms (D10-D36) were also searched. The following ICD-10 codes were not considered possible localizations of NETs: D18, C81 to C96, D33, C69 to C72, C46, C43, D03
GEP-NETs gastroenteropancreatic neuroendocrine tumors, ICD-10 International Classification of Diseases, Tenth Revision, LAN lanreotide autogel, NETs neuroendocrine tumors, OCT octreotide long-acting release
aChi-squared test
bStudent’s t test
cNo other localization of digestive NETs identified